Saturday, September 23, 2017 5:26:30 PM
September 23rd, 2017 - Filed Under - by Stacy Sanders
Cantor Fitzgerald reaffirmed their buy rating on shares of Versartis, Inc. (NASDAQ:VSAR) in a report issued on Friday. They currently have a $14.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $34.00.
https://www.dailypolitical.com/2017/09/23/versartis-inc-vsar-given-buy-rating-at-cantor-fitzgerald.html
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM